Ghent’s manufacturing network, including the nearby Obelisc site, supports an end-to-end cell therapy platform and collaborative ecosystem with FIT, VOKA, VIB, and Ghent University to advance science and industry.

Company leadership emphasizes the Belgium–Flanders partnership as a key driver of global manufacturing and patient-access strategy for CAR-T therapies, including cilta-cel (CARVYKTI) and broader pipeline development.

Ghent operations have scaled from two employees in 2022 to more than 1,000 across 66 nationalities, with ongoing hiring planned in the coming years.

Legend Biotech was named Foreign Investor of the Year at the 2025 Flanders International Business Awards, recognizing its long-term commitment, economic contributions, and job creation in Flanders.

The recognition solidifies Legend Biotech’s role in shaping Flanders as a global biotech hub and a cornerstone of Europe’s manufacturing ecosystem.

Legend Biotech, in a major move with Johnson & Johnson, has secured a €165 million joint investment to expand its Ghent Tech Lane facility, reinforcing Ghent as one of Europe’s largest CAR-T manufacturing centers and positioning the region as the European hub for clinical and commercial supply across the EMEA market.

The press release carries standard forward-looking statements with cautions about risks, and it provides investor contact information for follow-up inquiries.

Legend Biotech is a leading cell therapy company with a growing EU footprint for cilta-cel (CAR-T) in adults with relapsed or refractory multiple myeloma, while pursuing broader innovation across its cell therapy modalities and pipeline.